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c Duke-NUS Medical School, National University of Singapore, SingaporeWe thank Dr. Fukami for his Commentary [1] which nicely summa- use of an androgen dependent marker such as APOD as a potential pre-
rises the essentials of our study [2] and is well placed in the context of
the challenges facing clinicians in the management of PAIS patients
raised male. We would wish to take issue, however, with the emphasis
placed on testicular dysfunction and somatic mosaicism of the AR as
possible contributors to the phenotypic variation observed in PAIS.
The study of [3] is quoted with respect to evidence of testicular dys-
function in some cases of PAIS. We did not design our study specifically
to assess the characteristics of pituitary-gonadal functionwhich arewell
known in AIS, particularly the CAIS form. An undescended testis which
is often longstanding inAIS does not impair Leydig cell testosteronepro-
duction in general, in contrast to Sertoli and germ cell function. Indeed,
adult women with CAIS who have not been gonadectomised have tes-
tosterone concentrations well within or above the normal adult male
range. An elevated random T:LH ratio may be a biochemical indicator
of androgen resistance and indeed was tried, unsuccessfully, in the
past as a screen for mild androgen insensitivity syndrome (MAIS) asso-
ciatedwith idiopathicmale factor infertility (unpublished). However, in
view of the lack of precision and specificity in such measurements, we
do not see how blood hormone levels could be used as biomarkers for
pubertal outcome in PAIS. The other point made by Dr. Fukami in rela-
tion to somatic mosaicism has already been covered in the Discussion
where it was emphasised that this was highly unlikely in our cohort in
view of the number of familial cases andmost having had investigations
undertaken on DNA extracted from both blood and genital skin fibro-
blasts. While we do agree that the possibility of somatic mosaicism
should not be ignored, its low prevalence is unlikely to be a significant
contributor to the common phenotypic variability seen in PAIS. TheDOIs of original article: https://doi.org/10.1016/j.ebiom.2018.09.047, https://doi.org/
10.1016/j.ebiom.2018.10.026.
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Partial Androgen Insensitivit..., EBioMedicine (2018), https://doi.org/10.10dictor is certainly worth exploring further following the preliminary
studies of [4] in both CAIS and PAIS cases, as well as in patients with a
PAIS phenotype but no AR mutation.
In his Commentary, Dr. Fukami goes beyond the scope of the subject
of our study by emphasising the importance of assessing the psycholog-
ical aspects of the continuum of DSD, of which PAIS is only one of nu-
merous examples. He raises the problem of identifying predictors of
gender as opposed to somatic development in PAIS, a challenge which
at present appears insurmountable. We strongly echo his call for pro-
spective, multicentre-based international studies to capitalise on re-
sources such as the I-DSD registry and the DSD Translational Research
Network in the United States to garner robust outcome data that leads
to improved care for patients with PAIS across the lifespan.References
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